Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues

Nuclear Medicine and Biology

Volumn 33, Issue 6, 2006, Pages 723-733

  Miao, Yubin ^a,b   Fisher, Darrell R ^c   Quinn, Thomas P ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Alpha melanocyte stimulating hormone; Radiolabeled peptide; Radionuclide therapy of melanoma; Renal uptake

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM[2 GLUTAMYL 11 ARGININE]ALPHA MELANOCYTE STIMULATING HORMONE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM[2 GLUTAMYL 11 ARGININE]ALPHA MELANOCYTE STIMULATING HORMONE Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN;

ALPHA-MSH; ANIMALS; KIDNEY; LUTETIUM; MELANOMA; MICE; MICE, INBRED C57BL; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 33747373593     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.06.005     Document Type: Article

References (39)

1. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 5 (1999) 3608-3616
2. 3-octreotide. Eur J Nucl Med 28 (2001) 426-434
3. De Jong M., Valkema R., Jamar F., Kvols L.K., Kwekkeboom D.J., Breeman W.A.P., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
4. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 46 (2005) 121-129
5. Volkert W.A., Goeckeler W.F., Ehrhardt G.J., and Ketring A.R. Therapeutic radionuclides: production and decay property consideration. J Nucl Med 32 (1991) 174-185
6. Mørgenson C.E., and Sølling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 37 (1977) 477-486
7. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev 68 (1988) 912-986
8. Maack T., Johnson V., Kan S.T., Figueiredo J., and Sigulem D. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int 16 (1979) 251-270
9. 1-octreotide. Bioconjug Chem 9 (1998) 192-200
10. Duncan J.R., and Welch M.J. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34 (1993) 1728-1738
11. 111In-DTPA-ε-lysine as the primary metabolic and excretory product. Nucl Med Biol 21 (1994) 1023-1034
12. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res (suppl) 55 (1995) 5714s-5720s
13. Arano Y., Fujioka Y., Akizawa H., Ono M., Uehara T., Wakisaka K., et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 59 (1999) 128-134
14. Kobayashi H., Le N., Kim I.S., Kim M.-K., Pie J.-E., Drumm D., et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res 59 (1999) 422-430
15. Behr T.M., Sharkey R.M., Juweid M.E., Blumenthal R.D., Dunn R.M., Bair H.J., et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55 (1995) 3825-3834
16. Behr T.M., Becker W.S., Sharkey R.M., Juweid M.E., Dunn R.M., Bair H.J., et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 37 (1996) 829-833
17. Bernard B.F., Krenning E.P., Breeman W.A.P., Rolleman E.J., Bakker W.H., Visser T.J., et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38 (1997) 1929-1933
18. Rolleman E.J., Valkema R., De Jong M., Kooij P.P., and Krenning E.P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30 (2003) 9-15
19. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19 (2001) 3622-3634
20. Giblin M.F., Wang N.N., Hoffman T.J., Jurisson S.S., and Quinn T.P. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A 95 (1998) 12814-12818
21. 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res 60 (2000) 5649-5658
22. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101 (2002) 480-487
23. Miao Y., Whitener D., Feng W., Owen N.K., Chen J., and Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 14 (2003) 1177-1184
24. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 42 (2001) 1847-1855
25. 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem 45 (2002) 3048-3056
26. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 32 (2005) 485-493
27. Schubiger P.A., Alberto R., and Smith A. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7 (1996) 165-179
28. 90Y-SMT 487) eradicates experimental rat pancreatic CA20948 tumors. Eur J Nucl Med 25 (1998) 668-674
29. Hnatowich D.J., Virzi F., and Doherty P.W. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med 26 (1985) 503-509
30. Hui T.E., Fisher D.R., Kuhn J.A., Williams L.E., Nourigat C., Badger C.C., et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer 73 Suppl (1994) 951-957
31. 90Y-labeled immunoconjugate. Cancer 73 Suppl (1994) 958-965
32. Milenic D.E., Brady E.D., and Brechbiel M.W. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3 (2004) 488-499
33. Béhé M., Kluge G., Becker W., Gotthardt M., and Behr T.M. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46 (2005) 1012-1015
34. 111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 45 (2004) 709-713
35. 111In-DTPA-octreotide. J Nucl Med 46 (2005) 1696-1700
36. 90Y-labeled analogue. Eur J Nucl Med 26 (1999) 358-366
37. 11), a cyclized peptide analogue of α-MSH. J Med Chem 48 (2005) 2985-2992
38. Miao Y., Hylarides M., Fisher D.R., Shelton T., Moore H., Wester D.W., et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res 11 (2005) 5616-5621
39. De Jong M., Valkema R., Jamar F., Kvols L.K., Kwekkeboom D.J., Breeman W.A.P., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140